Free tool
FAERS Monitor: Dantrium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017443 or its brand name (Dantrium, Dantrolene Sodium). Reports on generic versions are filed under their own applications.
Reports
1,138
Serious
998
88% of reports
Hospitalization
547
Death reported
124
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neuroleptic malignant syndrome79
- pyrexia63
- pneumonia61
- asthenia59
- drug ineffective59
- respiratory failure59
- off label use54
- urinary tract infection52
- vomiting52
- diarrhoea49
- muscular weakness45
- nausea45
- convulsion41
- fatigue41
- hypertension35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 47 |
| 2006 | 54 |
| 2007 | 49 |
| 2008 | 59 |
| 2009 | 62 |
| 2010 | 61 |
| 2011 | 81 |
| 2012 | 83 |
| 2013 | 73 |
| 2014 | 43 |
| 2015 | 46 |
| 2016 | 63 |
| 2017 | 57 |
| 2018 | 45 |
| 2019 | 53 |
| 2020 | 42 |
| 2021 | 31 |
| 2022 | 36 |
| 2023 | 35 |
| 2024 | 27 |
| 2025 | 30 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,021 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuroleptic malignant syndromeSignal | 79 | 123.9 | 100.1 | 9,453 |
| respiratory failureSignal | 59 | 15.0 | 11.7 | 757 |
| convulsionSignal | 41 | 13.3 | 9.8 | 453 |
| muscular weaknessSignal | 45 | 7.3 | 5.5 | 240 |
| urinary tract infectionSignal | 52 | 5.6 | 4.3 | 195 |
| pneumoniaSignal | 61 | 3.5 | 2.7 | 107 |
| pyrexiaSignal | 63 | 3.4 | 2.6 | 104 |
| hypertensionSignal | 35 | 3.1 | 2.2 | 47 |
| astheniaSignal | 59 | 2.9 | 2.3 | 73 |
| vomitingSignal | 52 | 2.0 | 1.6 | 27 |
| diarrhoea | 49 | 1.4 | 1.1 | 5 |
| off label use | 54 | 1.1 | 0.9 | 1 |
| nausea | 45 | 1.1 | 0.8 | 0 |
| fatigue | 41 | 1.0 | 0.7 | 0 |
| drug ineffective | 59 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.